Improvement in disability after alemtuzumab treatment of multiple sclerosis is associated with neuroprotective autoimmunity.

@article{Jones2010ImprovementID,
  title={Improvement in disability after alemtuzumab treatment of multiple sclerosis is associated with neuroprotective autoimmunity.},
  author={Joanne L Jones and Jane Marian Anderson and Chia-Ling Phuah and Edward J. Fox and Krzysztof W. Selmaj and David H. Margolin and Stephen L. Lake and Jeffrey S. Palmer and Sara A. J. Thompson and Alastair Wilkins and Daniel J. Webber and D. Alastair S. Compston and Alasdair Coles},
  journal={Brain : a journal of neurology},
  year={2010},
  volume={133 Pt 8},
  pages={
          2232-47
        }
}
Treatment of early relapsing-remitting multiple sclerosis with the lymphocyte-depleting humanized monoclonal antibody alemtuzumab (Campath [registered trade mark]) significantly reduced the risk of relapse and accumulation of disability compared with interferon β-1a in a phase 2 trial [Coles et al., (Alemtuzumab vs. interferon β-1a in early multiple sclerosis. N Engl J Med 2008; 359: 1786-801)]. Patients treated with alemtuzumab experienced an improvement in disability at 6 months that was… CONTINUE READING

Citations

Publications citing this paper.
SHOWING 1-10 OF 76 CITATIONS, ESTIMATED 49% COVERAGE

Intractable and highly active relapsing multiple sclerosis – role of alemtuzumab

  • Neuropsychiatric disease and treatment
  • 2015
VIEW 2 EXCERPTS
CITES METHODS
HIGHLY INFLUENCED

Role of Regulatory T Cells in Pathogenesis and Biological Therapy of Multiple Sclerosis

  • Mediators of inflammation
  • 2013
VIEW 5 EXCERPTS
CITES BACKGROUND
HIGHLY INFLUENCED

FILTER CITATIONS BY YEAR

2010
2019

CITATION STATISTICS

  • 8 Highly Influenced Citations

  • Averaged 5 Citations per year over the last 3 years

References

Publications referenced by this paper.
SHOWING 1-10 OF 48 REFERENCES

The window of therapeutic opportunity in multiple sclerosis

  • Journal of Neurology
  • 2005
VIEW 7 EXCERPTS
HIGHLY INFLUENTIAL

Alemtuzumab vs. interferon beta-1a in early multiple sclerosis.

  • The New England journal of medicine
  • 2008
VIEW 3 EXCERPTS
HIGHLY INFLUENTIAL

Similar Papers

Loading similar papers…